Ben Greenblum focuses his practice in complex civil litigation, with an emphasis on antitrust and intellectual property disputes. Ben litigates on behalf of corporations and individuals in federal and state courts across the country, and has served as lead defense counsel in several multidistrict litigation and other complex proceedings.
In 2014, Ben was part of the trial team that defended an international pharmaceutical company from a $60 billion antitrust claim alleging a so-called “reverse payment” patent settlement. The case was the first of its kind to go to trial, and to date the only of its kind to go to verdict. The jury’s verdict for the defense was affirmed on appeal. Since then, Ben has represented several pharmaceutical firms in various high stakes antitrust disputes.